Pre-Conference Focus Day
This dedicated focus day will explore circulating tumor DNA in gastrointestinal cancer - from a patient selection, prognostic and therapeutic response perspective to aid the unmet need for early and specific detection, determining correct treatment plans, and optimizing drug performance for the best outcome in GI cancers.
11:55 am Chair’s Opening Remarks: Setting the Scene – The Transition to Liquid Biopsy & What is ctDNA, How Has Precision Oncology Utilized it for Liquid Biopsy?
- Nuzhat Pathan Senior Director, Translational Oncology, Pfizer
- What are the recent technical advancements in liquid biopsy & how have they offered clinicians and drug developers benefit to their patients?
- How has the rapidly expanding landscape of ctDNA been used in screening, early detection & disease monitoring in GI cancers?
- What barriers are preventing wider adoption in clinical trial programs and real-world practice?
- The importance of understanding the challenges of sensitivity & specificity for early-stage disease
A Case Study-Led Look into Developing ctDNA as a Diagnostic/Patient Selection Tool in GI Cancer
12:00 pm The Role of Extrachromosomal DNA (ecDNA) in Amplification Driven Solid Tumors
- Jason Christiansen Chief Technology Officer, Boundless Bio
- What ecDNA is and the functional implications of ecDNA in cancer
- How ecDNA driven tumors have evaded previous targeted drug approaches. New drug approaches need to be developed, in a precision medicine fashion, to target these tumors
- Assessing ecDNA in tumors is part of the precision strategy, and to be complete, methods for circulating ecDNA measurements must be developed to both diagnose and monitor
12:30 pm The Power of a Personalized ctDNA Assay for MRD Detection & Monitoring in GI Cancers
- Dr. Angel Rodriguez, MD Oncology Medical Director, Natera
- Dr. John Simmons, PhD Global Vice President, Biopharma Business Development, Natera
1:00 pm Networking Lunch
A Case Study-Led Look into Developing ctDNA as a Prognostic Tool in GI Cancer
2:00 pm NCI SBIR: Accelerating Cancer Technologies From Lab to Market
- Xing-Jian Lou Program Director, National Cancer Institute
- The SBIR & STTR Programs are one of the largest sources of early-stage technology financing in the United States
- The SBIR & STTR Funds are non-dilutive, no strings attached
- Solutions for cancers with low survival rates, such as pancreatic adenocarcinoma are particularly encouraged to apply
2:30 pm Live CTC Genomics for Gastric Cancer Therapy Predictions
- Vanathi Perumal Research Fellow, Sir Charles Gairdner Hospital
- As incidental findings, viable CTC and tumour spheres were cultured in cancer risk patients for custom made drug testing
- Established single step viable head and neck cancer CTC and tumour spheres count for radiotherapy predictions
- In translating our peer-reviewed findings, cancer risk viable CTC and tumour spheres were tested for SFRP4, cisplatin and combination treatment towards sensitisation approach
3:00 pm Networking Break
Case Study-Led Look into Developing ctDNA as a Therapeutic Response Tool to Spearhead Your Pipeline
3:30 pm Revealing The Hidden
- Berke Olcaysoy Molecular Biologist, Acibadem Healthcare Group
- Circulating tumor DNA has much to offer but is hard to extract. Techniques with greater precision reveal the hidden or suppressed warnings in the blood
- Logistics and sample handling can affect the output data, a universal standard is definitely needed
- Cancer treatment is a continuous process; every patient needs to be monitored with molecular assays before, during and after the intervention
4:00 pm ctDNA Analysis for Molecular Profiling & Treatment Monitoring in GI Cancer
- Tae-You Kim Professor, Division of Medical Oncology & Founder & CEO, Seoul National University Hospital & IMB Diagnostics
- ctDNA analysis as a powerful tool to capture tumor heterogeneity and clonal evolution
- Application of ctDNA analysis across the continuum of cancer care
- Emerging technology of genome-wide methylation and fragmentomics for early cancer detection and screening